RU2009134137A - Нейрогенные соединения - Google Patents
Нейрогенные соединения Download PDFInfo
- Publication number
- RU2009134137A RU2009134137A RU2009134137/21A RU2009134137A RU2009134137A RU 2009134137 A RU2009134137 A RU 2009134137A RU 2009134137/21 A RU2009134137/21 A RU 2009134137/21A RU 2009134137 A RU2009134137 A RU 2009134137A RU 2009134137 A RU2009134137 A RU 2009134137A
- Authority
- RU
- Russia
- Prior art keywords
- group
- sugar
- compound
- gallate
- fructose
- Prior art date
Links
- 150000001875 compounds Chemical class 0.000 title claims abstract 23
- 230000001272 neurogenic effect Effects 0.000 title claims abstract 3
- OWEGMIWEEQEYGQ-UHFFFAOYSA-N 100676-05-9 Natural products OC1C(O)C(O)C(CO)OC1OCC1C(O)C(O)C(O)C(OC2C(OC(O)C(O)C2O)CO)O1 OWEGMIWEEQEYGQ-UHFFFAOYSA-N 0.000 claims abstract 20
- 229930091371 Fructose Natural products 0.000 claims abstract 20
- RFSUNEUAIZKAJO-ARQDHWQXSA-N Fructose Chemical compound OC[C@H]1O[C@](O)(CO)[C@@H](O)[C@@H]1O RFSUNEUAIZKAJO-ARQDHWQXSA-N 0.000 claims abstract 20
- 239000005715 Fructose Substances 0.000 claims abstract 20
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 claims abstract 20
- GUBGYTABKSRVRQ-PICCSMPSSA-N Maltose Natural products O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@@H](CO)OC(O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-PICCSMPSSA-N 0.000 claims abstract 20
- WQZGKKKJIJFFOK-PHYPRBDBSA-N alpha-D-galactose Chemical compound OC[C@H]1O[C@H](O)[C@H](O)[C@@H](O)[C@H]1O WQZGKKKJIJFFOK-PHYPRBDBSA-N 0.000 claims abstract 20
- GUBGYTABKSRVRQ-QUYVBRFLSA-N beta-maltose Chemical compound OC[C@H]1O[C@H](O[C@H]2[C@H](O)[C@@H](O)[C@H](O)O[C@@H]2CO)[C@H](O)[C@@H](O)[C@@H]1O GUBGYTABKSRVRQ-QUYVBRFLSA-N 0.000 claims abstract 20
- 229930182830 galactose Natural products 0.000 claims abstract 20
- 239000008103 glucose Substances 0.000 claims abstract 20
- 125000002791 glucosyl group Chemical group C1([C@H](O)[C@@H](O)[C@H](O)[C@H](O1)CO)* 0.000 claims abstract 20
- 229910052739 hydrogen Inorganic materials 0.000 claims abstract 20
- 239000001257 hydrogen Substances 0.000 claims abstract 20
- 150000002431 hydrogen Chemical class 0.000 claims abstract 17
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims abstract 15
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims abstract 3
- 239000002207 metabolite Substances 0.000 claims abstract 3
- 150000003839 salts Chemical class 0.000 claims abstract 3
- LMBFAGIMSUYTBN-MPZNNTNKSA-N teixobactin Chemical compound C([C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H](CCC(N)=O)C(=O)N[C@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H](CO)C(=O)N[C@H]1C(N[C@@H](C)C(=O)N[C@@H](C[C@@H]2NC(=N)NC2)C(=O)N[C@H](C(=O)O[C@H]1C)[C@@H](C)CC)=O)NC)C1=CC=CC=C1 LMBFAGIMSUYTBN-MPZNNTNKSA-N 0.000 claims abstract 3
- 230000004770 neurodegeneration Effects 0.000 claims 2
- 208000015122 neurodegenerative disease Diseases 0.000 claims 2
- 208000024827 Alzheimer disease Diseases 0.000 claims 1
- 208000004793 anterograde amnesia Diseases 0.000 claims 1
- 201000010099 disease Diseases 0.000 claims 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 1
- 206010013395 disorientation Diseases 0.000 claims 1
- 210000001320 hippocampus Anatomy 0.000 claims 1
- 230000001537 neural effect Effects 0.000 claims 1
- 230000004766 neurogenesis Effects 0.000 claims 1
- 230000037081 physical activity Effects 0.000 claims 1
- 239000002243 precursor Substances 0.000 claims 1
- 201000009570 retrograde amnesia Diseases 0.000 claims 1
- 230000004936 stimulating effect Effects 0.000 claims 1
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 abstract 6
- 0 *c1c(*)cc(C(C(C23)O)[C@@]2Oc(c(*)c(*)c(*)c2*)c2C3=O)cc1 Chemical compound *c1c(*)cc(C(C(C23)O)[C@@]2Oc(c(*)c(*)c(*)c2*)c2C3=O)cc1 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/24—Antidepressants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Medicinal Chemistry (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Biomedical Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Psychiatry (AREA)
- Molecular Biology (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US90123907P | 2007-02-14 | 2007-02-14 | |
| US60/901,239 | 2007-02-14 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| RU2009134137A true RU2009134137A (ru) | 2011-03-27 |
Family
ID=39763345
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2009134137/21A RU2009134137A (ru) | 2007-02-14 | 2008-02-13 | Нейрогенные соединения |
Country Status (9)
| Country | Link |
|---|---|
| US (1) | US20080227829A1 (enExample) |
| EP (2) | EP2117306A4 (enExample) |
| JP (1) | JP2010518164A (enExample) |
| CN (1) | CN101951768A (enExample) |
| AU (1) | AU2008257437A1 (enExample) |
| CA (1) | CA2677892A1 (enExample) |
| IL (1) | IL200383A0 (enExample) |
| RU (1) | RU2009134137A (enExample) |
| WO (1) | WO2008147483A2 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8349832B2 (en) * | 2009-09-02 | 2013-01-08 | Canthera Therapeutics | Compounds and compositions for treating cancer |
| US8318737B2 (en) | 2009-09-02 | 2012-11-27 | Canthera Therapeutics Inc. | Compounds and compositions for treating cancer |
| EP2473506A4 (en) | 2009-09-02 | 2013-03-06 | Canthera Therapeutics Inc | COMPOUNDS AND METHOD FOR THE TREATMENT OF CANCER |
| CN102711743A (zh) | 2009-10-22 | 2012-10-03 | Api起源有限责任公司 | 含有黄酮类的组合物的制备和使用方法 |
| BR112013010958A8 (pt) | 2010-10-22 | 2017-10-03 | Api Genesis Llc | Métodos para elevar a solubilidade de compostos pouco solúveis e métodos para fabricação e para uso de formulações de tais compostos |
| EP3202398B1 (en) | 2011-06-17 | 2019-12-25 | Ludwig Aigner | Chromane-like cyclic prenylflavonoids for the medical intervention in neurological disorders |
| US10059956B2 (en) * | 2012-01-17 | 2018-08-28 | Suntory Holdings Limited | Glycosyltransferase gene and use thereof |
| WO2016072522A1 (ja) * | 2014-11-06 | 2016-05-12 | 国立大学法人 長崎大学 | 新規アルツハイマー病治療薬 |
| JP6207545B2 (ja) * | 2015-04-30 | 2017-10-04 | 丸大食品株式会社 | 学習記憶能力増強剤 |
| JP6842093B2 (ja) * | 2019-08-20 | 2021-03-17 | 丸大食品株式会社 | 学習記憶能力増強剤 |
| JP7754447B2 (ja) * | 2021-10-21 | 2025-10-15 | 松本 忠昌 | ストレスを軽減するための組成物 |
Family Cites Families (25)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB9317071D0 (en) * | 1993-08-17 | 1993-09-29 | Univ Strathclyde | Flavonoids |
| GB9521184D0 (en) * | 1995-10-17 | 1995-12-20 | Univ Strathclyde | Flavonoids |
| US6297273B1 (en) * | 1996-04-02 | 2001-10-02 | Mars, Inc. | Use of cocoa solids having high cocoa polyphenol content in tabletting compositions and capsule filling compositions |
| US5733926A (en) * | 1996-12-13 | 1998-03-31 | Gorbach; Sherwood L. | Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions |
| US5952374A (en) * | 1997-09-29 | 1999-09-14 | Protein Technologies International, Inc. | Method for inhibiting the development of Alzheimer's disease and related dementias- and for preserving cognitive function |
| US6482448B2 (en) * | 1998-07-16 | 2002-11-19 | Aaron Tabor | Soy formulations and their use for promoting health |
| WO2000017184A1 (en) * | 1998-09-24 | 2000-03-30 | Mitsubishi Chemical Corporation | Hydroxyflavone derivatives as tau protein kinase 1 inhibitors |
| US6451837B1 (en) * | 1999-09-01 | 2002-09-17 | Andrius Baskys | Neuroprotective effects of mitogen-activated protein kinase (MAPK) cascade inhibitors |
| US20010047032A1 (en) * | 1999-12-30 | 2001-11-29 | Castillo Gerardo M. | Polyhydroxylated aromatic compounds for the treatment of amyloidosis and alpha-synuclein fibril diseases |
| EP1127572A3 (en) * | 2000-02-25 | 2003-05-02 | Basf Aktiengesellschaft | Use of flavones for treating cycloxygenase-2 mediated diseases |
| GB2348371B (en) * | 2000-03-14 | 2001-04-04 | Soares Da Silva Patricio | Compositions comprising blockers of L-DOPA renal cell transfer for the treatment of Parkinson's disease |
| US6472436B1 (en) * | 2000-07-17 | 2002-10-29 | The Salk Institute For Biological Studies | Methods for protecting cells from amyloid toxicity and for inhibiting amyloid protein production |
| JP4633897B2 (ja) * | 2000-08-17 | 2011-02-16 | 長瀬産業株式会社 | 神経突起伸長剤 |
| US6733797B1 (en) * | 2000-11-15 | 2004-05-11 | William K. Summers | Neuroceutical for improving memory and cognitive abilities |
| WO2002076473A1 (en) * | 2001-03-26 | 2002-10-03 | Academy Of Military Medical Sciences Institute Of Pharmacology And Toxicology | Quercetin derivative and its medicinal use |
| DK1417211T3 (da) * | 2001-07-27 | 2007-10-08 | Neptune Technologies & Bioress | Naturlige phospholipider af marin oprindelse, der indeholder flavonoider og polyumættede phospholipider, og deres anvendelse |
| JP4609875B2 (ja) * | 2001-07-31 | 2011-01-12 | 有限会社大長企画 | 健康食品 |
| AU2003259220C1 (en) * | 2002-07-24 | 2017-08-24 | Australian Health & Nutrition Association Limited | Compositions and products containing enantiomeric equol, and methods for their making |
| US8138165B2 (en) * | 2002-10-22 | 2012-03-20 | Jenken Biosciences, Inc. | Chromones and chromone derivatives and uses thereof |
| US7763588B2 (en) * | 2003-06-13 | 2010-07-27 | The Salk Institute For Biological Studies | Method for increasing cognitive function and neurogenesis |
| WO2005020881A2 (en) * | 2003-09-01 | 2005-03-10 | Shanghai Comman Pharmaceutical Co. | Compositions of flavonoids and flavonoid-containing extracts and the treatment of diseases |
| KR100610562B1 (ko) * | 2004-06-28 | 2006-08-08 | 재단법인서울대학교산학협력재단 | 플라보노이드 유도체를 포함하는 급성 또는 만성 퇴행성뇌질환의 예방 또는 치료용 조성물 |
| US20060148727A1 (en) * | 2004-12-01 | 2006-07-06 | Curt Hendrix | Folate based composition for neurological and cognitive applications |
| US7442394B2 (en) * | 2005-05-02 | 2008-10-28 | University Of South Florida | Combined effects of nutrients on proliferation of stem cells |
| WO2008011538A2 (en) * | 2006-07-19 | 2008-01-24 | The Salk Institute For Biological Studies | Methods of using flavonoids to enhance memory |
-
2008
- 2008-02-13 AU AU2008257437A patent/AU2008257437A1/en not_active Abandoned
- 2008-02-13 CA CA002677892A patent/CA2677892A1/en not_active Abandoned
- 2008-02-13 RU RU2009134137/21A patent/RU2009134137A/ru not_active Application Discontinuation
- 2008-02-13 EP EP08825828A patent/EP2117306A4/en not_active Withdrawn
- 2008-02-13 EP EP12165032A patent/EP2478901A3/en not_active Withdrawn
- 2008-02-13 WO PCT/US2008/001914 patent/WO2008147483A2/en not_active Ceased
- 2008-02-13 JP JP2009549615A patent/JP2010518164A/ja active Pending
- 2008-02-13 CN CN200880011384XA patent/CN101951768A/zh active Pending
- 2008-02-13 US US12/069,861 patent/US20080227829A1/en not_active Abandoned
-
2009
- 2009-08-13 IL IL200383A patent/IL200383A0/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP2478901A3 (en) | 2012-11-14 |
| WO2008147483A2 (en) | 2008-12-04 |
| CA2677892A1 (en) | 2008-12-04 |
| EP2478901A2 (en) | 2012-07-25 |
| JP2010518164A (ja) | 2010-05-27 |
| CN101951768A (zh) | 2011-01-19 |
| AU2008257437A1 (en) | 2008-12-04 |
| WO2008147483A8 (en) | 2009-01-15 |
| EP2117306A4 (en) | 2010-02-10 |
| US20080227829A1 (en) | 2008-09-18 |
| WO2008147483A3 (en) | 2009-02-26 |
| WO2008147483A9 (en) | 2009-04-09 |
| IL200383A0 (en) | 2010-04-29 |
| EP2117306A2 (en) | 2009-11-18 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1118651T1 (el) | Αζακυκλικες ενωσεις για χρηση στην θεραπευτικη αντιμετωπιση ασθενειων που σχετιζονται με τη σεροτονινη | |
| RU2010113974A (ru) | Применение противовоспалительного пептида-1 в качестве терапевтического средства | |
| EA201270144A1 (ru) | Комбинированная терапия при лечении диабета | |
| EA201270292A1 (ru) | Терапия глатирамером ацетатом с низкой кратностью | |
| EA200602130A1 (ru) | Замещенные арилацилтиомочевины и родственные соединения; ингибиторы репликации вирусов | |
| JP2010518164A5 (enExample) | ||
| EA200601799A1 (ru) | Гидразидсодержащие соединения - ингибиторы cftr и их применение | |
| RU2010114024A (ru) | Применение гонадорелина в качестве терапевтического средства | |
| JP2011521940A5 (enExample) | ||
| RU2010113998A (ru) | Применение пептида rfmwmr в качестве терапевтического средства | |
| EA200601281A1 (ru) | Азабензофуранзамещенные тиомочевины; ингибиторы репликации вирусов | |
| ATE373679T1 (de) | Antimikrobiell wirksames oder endotoxin neutralisierendes polypeptid | |
| EA014055B1 (ru) | Применение пептидных соединений для лечения боли при раке кости, а также боли, вызванной химиотерапией и нуклеозидами | |
| EA200971073A1 (ru) | Применение ранолазина при повышенном уровне натрийуретического пептида мозгового типа | |
| EP1543158A4 (en) | REGULATED APTAMER THERAPEUTICS | |
| EA200601846A1 (ru) | Содержащие бензоксазины лекарственные комбинации для лечения заболеваний дыхательных путей | |
| ATE405272T1 (de) | Behandlung von t-zellen-lymphom mittels 10- propargyl-10-deazaaminopterin | |
| RU2008152746A (ru) | Лечение ишемических заболеваний с применением эритропоэтина | |
| RU2007119545A (ru) | Пегилированный липосомальный доксорубицин в комбинации с эктеинасцидином 743 (ecteinescidin 743) | |
| BRPI0409699A (pt) | métodos de indução do efeito diurético, de indução, manutenção ou restauração do efeito diurético de diurético não modificador de adenosina, de manutenção, restauração ou melhoria da função renal em paciente, de indução de diurese, de prevenção do inìcio de deficiência renal em paciente com sobrecarga de fluidos ou chf, de tratamento de paciente que sofre de chf e de melhoria dos resultados globais da saúde, composição farmacêutica e seus usos | |
| EP1352955A3 (en) | HLA matching donor-originating activated lymphocytes to be used in prevention/treatment of tumors, infectious diseases and autoimmune diseases, treatment method achieved by using the lymphocytes, formula having the lymphocytes as a main constitutuent thereof, method for manufacturing the formula and preparation kit to be used to prepare the formula | |
| RU2008103792A (ru) | Производное гликолипидов и лекарственное средство, содержащее это производное в качестве активного компонента | |
| RU2007111754A (ru) | Применение мидостаурина для лечения желудочно-кишечных стромальных опухолей | |
| ATE491474T1 (de) | Behandlung von neuropathischen schmerzen mittels eines n-methyl-d-aspartate (nmda)-rezeptor- antagonists | |
| RU2283110C1 (ru) | Способ премедикации у пациентов с вегетососудистой дистонией по гипотоническому типу при амбулаторных стоматологических вмешательствах |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA94 | Acknowledgement of application withdrawn (non-payment of fees) |
Effective date: 20130227 |